Glucan Particles for Macrophage Targeted Delivery of Nanoparticles

Overview

Journal J Drug Deliv

Date 2011 Oct 21

PMID 22013535

Citations 39

Authors

Ernesto R Soto

Abaigeal C Caras

Lindsey C Kut

Melissa K Castle

Gary R Ostroff

Affiliations

Soon will be listed here.

Abstract

Glucan particles (GPs) are hollow, porous 2-4 μm microspheres derived from the cell walls of Baker's yeast (Saccharomyces cerevisiae). The 1,3-β-glucan outer shell provides for receptor-mediated uptake by phagocytic cells expressing β-glucan receptors. GPs have been used for macrophage-targeted delivery of soluble payloads (DNA, siRNA, protein, and small molecules) encapsulated inside the hollow GPs via core polyplex and layer-by-layer (LbL) synthetic strategies. In this communication, we report the incorporation of nanoparticles as cores inside GPs (GP-NP) or electrostatically bound to the surface of chemically derivatized GPs (NP-GP). GP nanoparticle formulations benefit from the drug encapsulation properties of NPs and the macrophage-targeting properties of GPs. GP nanoparticle formulations were synthesized using fluorescent anionic polystyrene nanoparticles allowing visualization and quantitation of NP binding and encapsulation. Mesoporous silica nanoparticles (MSNs) containing the chemotherapeutic doxorubicin (Dox) were bound to cationic GPs. Dox-MSN-GPs efficiently delivered Dox into GP phagocytic cells resulting in enhanced Dox-mediated growth arrest.

Citing Articles

Targeted delivery of antitubercular drugs using glucan lipid particles.

Jaecklein E, Papavinasasundaram K, Ostroff G, Sassetti C, Soto E Microbiol Spectr. 2025; 13(3):e0274424.

PMID: 39912634 PMC: 11878006. DOI: 10.1128/spectrum.02744-24.

Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges.

Ren S, Xu Y, Dong X, Mu Q, Chen X, Yu Y J Nanobiotechnology. 2024; 22(1):431.

PMID: 39034407 PMC: 11265020. DOI: 10.1186/s12951-024-02670-7.

Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.

Ahmad F, Ahmad S, Upadhyay T, Singh S, Khubaib M, Singh J Sci Rep. 2024; 14(1):16437.

PMID: 39013991 PMC: 11253001. DOI: 10.1038/s41598-024-66634-5.

Oral bioavailability of a noncoding RNA drug, TY1, that acts on macrophages.

Yamaguchi S, Miyamoto K, Jones X, Ciullo A, Morris A, Tsi K bioRxiv. 2024; .

PMID: 38746093 PMC: 11092517. DOI: 10.1101/2024.04.27.591474.

Understanding yeast shells: structure, properties and applications.

Macedo L, Pinho S, Silva A, Moura I, Espinoza B, Invencao M ADMET DMPK. 2024; 12(2):299-317.

PMID: 38720922 PMC: 11075163. DOI: 10.5599/admet.2118.

References

Sun D . Nanotheranostics: integration of imaging and targeted drug delivery. Mol Pharm. 2010; 7(6):1879. DOI: 10.1021/mp1003652. View

Choi C, Alabi C, Webster P, Davis M . Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010; 107(3):1235-40. PMC: 2824286. DOI: 10.1073/pnas.0914140107. View

Thielbeer F, Donaldson K, Bradley M . Zeta potential mediated reaction monitoring on nano and microparticles. Bioconjug Chem. 2011; 22(2):144-50. DOI: 10.1021/bc1005015. View

Plank C, Zatloukal K, Cotten M, Mechtler K, Wagner E . Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug Chem. 1992; 3(6):533-9. DOI: 10.1021/bc00018a012. View

Aouadi M, Tesz G, Nicoloro S, Wang M, Chouinard M, Soto E . Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009; 458(7242):1180-4. PMC: 2879154. DOI: 10.1038/nature07774. View

Patri A, Myc A, Beals J, Thomas T, Bander N, Baker Jr J . Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem. 2004; 15(6):1174-81. DOI: 10.1021/bc0499127. View

Owens 3rd D, Peppas N . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2005; 307(1):93-102. DOI: 10.1016/j.ijpharm.2005.10.010. View

Wang X, Li J, Wang Y, Cho K, Kim G, Gjyrezi A . HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano. 2009; 3(10):3165-74. PMC: 3733355. DOI: 10.1021/nn900649v. View

Zhao H, Heindel N . Determination of degree of substitution of formyl groups in polyaldehyde dextran by the hydroxylamine hydrochloride method. Pharm Res. 1991; 8(3):400-2. DOI: 10.1023/a:1015866104055. View

10.

Huang H, Ostroff G, Lee C, Wang J, Specht C, Levitz S . Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun. 2009; 77(5):1774-81. PMC: 2681737. DOI: 10.1128/IAI.00086-09. View

11.

Petros R, DeSimone J . Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9(8):615-27. DOI: 10.1038/nrd2591. View

12.

Meng H, Liong M, Xia T, Li Z, Ji Z, Zink J . Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 2010; 4(8):4539-50. PMC: 3899722. DOI: 10.1021/nn100690m. View

13.

Choi H, Liu W, Misra P, Tanaka E, Zimmer J, Ipe B . Renal clearance of quantum dots. Nat Biotechnol. 2007; 25(10):1165-70. PMC: 2702539. DOI: 10.1038/nbt1340. View

14.

Hamad I, Hunter A, Rutt K, Liu Z, Dai H, Moghimi S . Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol. 2008; 45(14):3797-803. PMC: 2824540. DOI: 10.1016/j.molimm.2008.05.020. View

15.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View

16.

Lu J, Liong M, Zink J, Tamanoi F . Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007; 3(8):1341-6. DOI: 10.1002/smll.200700005. View

17.

Han L, Huang R, Liu S, Huang S, Jiang C . Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm. 2010; 7(6):2156-65. DOI: 10.1021/mp100185f. View

18.

Low P, Henne W, Doorneweerd D . Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2007; 41(1):120-9. DOI: 10.1021/ar7000815. View

19.

Malam Y, Lim E, Seifalian A . Current trends in the application of nanoparticles in drug delivery. Curr Med Chem. 2011; 18(7):1067-78. DOI: 10.2174/092986711794940860. View

20.

Marshall A, Willment J, Lin H, Williams D, Gordon S, Brown G . Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem. 2004; 279(15):14792-802. DOI: 10.1074/jbc.M313127200. View